Neurotoxin-based models of Parkinson's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review of animal models and preclinical literature without original human data
PubMed 22108613 · doi:10.1016/j.neuroscience.2011.10.057
What was done
This is a narrative review evaluating neurotoxin-based animal models of Parkinson's disease (PD), specifically examining 6-hydroxydopamine (6-OHDA) rodent models, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate and mouse models, and paraquat and rotenone rodent models. The authors assess their contributions to understanding basal ganglia pathology, developing symptomatic treatments, and evaluating pathogenic mechanisms.
What was found
The abstract reports no numerical data. Qualitatively, 6-OHDA and MPTP models contributed to translating symptomatic treatments into clinical practice, including pharmacological therapies and subthalamic nucleus deep brain stimulation. However, none of the preclinical neuroprotective strategies have successfully translated to clinical settings to treat PD patients, leaving these models unvalidated as screening tools for neuroprotection.
Why it matters
It highlights a critical translational gap in Parkinson's research: neurotoxin animal models have enabled effective symptomatic and surgical therapies but have failed to predict disease-modifying or neuroprotective efficacy in human patients.
Limits
The abstract presents a narrative review of animal studies without quantitative data or systematic search methods. Neurotoxin-induced animal models do not fully replicate the complex, progressive neurodegenerative features of human Parkinson's disease.
Cited by
- context Paraquat is used experimentally in research laboratories to induce Parkinson's disease in non-human primates.